PubMed · 1993 · 32 citations · 0 references
MedicineHematologyNephrologyCardiac TransplantationRenal PathophysiologyTransplant ImmunologyHeart Transplant PharmacotherapyHeart TransplantationHemolytic DisordersPost-transplant ComplicationsTransplant PharmacologyTransplant RejectionAcute Cardiac Allograft RejectionCyclosporine PharmacokineticsHeart Transplant Recipient AssessmentPost-transplant ImmunosuppressionRenal Dysfunction After Transplant
We report a case of hemolytic uremic syndrome associated with the use of cyclosporine in a heart transplant recipient. The patient manifested many classic signs and symptoms of hemolytic uremic syndrome, and a diagnosis was confirmed by kidney biopsy. Treatment with plasma exchange was effective in halting the hemolysis, but renal function failed to improve. Rechallenge with cyclosporine caused recurrence of microangiopathic hemolysis. Because of concerns regarding allograft rejection, an experimental immunosuppressive agent, RS-61443, was used that was effective in controlling rejection and was not associated with recurrence of hemolytic uremic syndrome.